San­doz to pay Al­ler­gan, Duke Uni­ver­si­ty $39M over eye drug law­suit, ju­ry says

San­doz is on the hook for $39 mil­lion to Al­ler­gan and Duke Uni­ver­si­ty for in­fring­ing on their patent for an eye­lash-growth drug, Latisse (bi­mato­prost oph­thalmic so­lu­tion), a Col­orado fed­er­al ju­ry de­cid­ed Fri­day.

In a com­plaint filed by Al­ler­gan and Duke against San­doz, Al­ler­gan said that since its launch in 2016, San­doz’s gener­ic ver­sion of Latisse has caused sales of Al­ler­gan’s prod­uct to de­cline by around 50% in Texas. Net sales for Al­ler­gan from Latisse were over $70 mil­lion an­nu­al­ly from its launch in 2009 up to 2018, when the com­plaint was filed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.